Back
BioAtla, Inc. 10K Form
Sell
37
BCAB
BioAtla, Inc.
Last Price:
$0.76
Seasonality Move:
-42.47%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive BCAB News And Ratings
See the #1 stock for the next 7 days that we like better than BCAB
BCAB Financial Statistics
Sales & Book Value
| Annual Sales: | $11M |
|---|---|
| Cash Flow: | $-9.9M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.53 |
| Price / Book: | 38.72 |
Profitability
| EPS (TTM): | -1.14960 |
|---|---|
| Net Income (TTM): | $-64.7M |
| Gross Margin: | $10.1M |
| Return on Equity: | -567.84% |
| Return on Assets: | -165.08% |
BioAtla, Inc. Earnings Forecast
Key BioAtla, Inc. Financial Ratios
-
The Gross Profit Margin over the past 7 years for BCAB is 91.59%.
-
The Selling, General & Administrative Expenses for BCAB have been equal to 198.62% of Gross Profit Margin.
-
The Research & Development expenses have been 573.59% of Revenue.
-
The Net Earning history of BCAB is -634.33% of Total Revenues.
-
Per Share Earnings over the last 7 years have been positive in 3 years.
BioAtla, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | BCAB |
| CUSIP: | 09077B |
| Website: | BioAtla.com |
Debt
| Debt-to-Equity Ratio: | -0.2 |
|---|---|
| Current Ratio: | 0.54 |
| Quick Ratio: | 0.46 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
BCAB Technical Analysis vs Fundamental Analysis
Sell
37
BioAtla, Inc. (BCAB)
is a Sell
Is BioAtla, Inc. a Buy or a Sell?
-
BioAtla, Inc. stock is rated a SellThe current BioAtla, Inc. [BCAB] share price is $0.75. The Score for BCAB is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.